AAAAI Advocates for Penicillin Allergy De-labeling
News related to:The American Academy of Allergy, Asthma & Immunology (AAAAI) · 3 min read
MILWAUKEE, Sept. 22, 2026 /CourierPR/ -- September 28 marks National Penicillin Allergy Day, a day dedicated to raising awareness about the importance of accurately diagnosing and managing penicillin allergies. The American Academy of Allergy, Asthma & Immunology (AAAAI) is the leading organization in this field, and it is committed to ensuring that patients receive the best possible care by advocating for the de-labeling of unnecessary penicillin allergy diagnoses.
More than 90% of patients with a documented penicillin allergy in their electronic medical records can safely take penicillin after a thorough evaluation. However, many patients are still labeled with a penicillin allergy, which can lead to unnecessary antibiotic treatments and even prevent them from receiving effective care for certain infections. This can have serious consequences, including the development of antibiotic-resistant bacteria, which is a growing concern in the medical community.
The AAAAI is taking a proactive approach to address this issue by providing valuable resources and educational materials to medical professionals. These resources include podcasts, informative videos, social media graphics, practice resources, and more, all designed to help healthcare providers question the diagnosis, evaluate the allergy, and improve patient care.
The AAAAI's Penicillin Allergy Center is a key resource for medical professionals. It offers a comprehensive range of materials that can be used to educate patients and their families about penicillin allergy de-labeling. These materials are designed to be easily accessible and can be used in various settings, such as clinics, hospitals, and educational events.
In addition to these resources, the AAAAI has also developed a Penicillin Allergy Position Statement, which provides detailed information about the safety of penicillin allergy testing for both children and adults. The statement emphasizes the importance of accurate diagnosis and the potential benefits of de-labeling unnecessary penicillin allergies.
The AAAAI is also advocating for the PAVE Act (H.R. 5736), a bipartisan bill that would require penicillin allergy verification and evaluation to be included in Medicare's Initial Preventative Physical Exam (IPPE) and Annual Wellness Visit (AWV). The AAAAI has partnered with members of Congress to support this legislation, which aims to improve patient outcomes and reduce healthcare costs.
The AAAAI is not alone in its efforts to address penicillin allergy issues. The organization is actively engaging with the public through its advocacy platform, AAAAI Advocate, to encourage members of Congress to support the PAVE Act. This platform allows individuals to easily reach out to their representatives and express their support for the bill.
The AAAAI is also exploring additional advocacy initiatives in the fight against antibiotic and antimicrobial resistance. These initiatives aim to raise awareness about the importance of proper antibiotic use and to promote the development of new treatments to combat antibiotic-resistant bacteria.
The AAAAI is committed to serving as a trusted source of information regarding penicillin allergy and its effects on public health. By providing these resources and advocating for the PAVE Act, the AAAAI is working to ensure that patients receive the best possible care and that unnecessary penicillin allergies are identified and addressed.
In conclusion, National Penicillin Allergy Day is a crucial opportunity to raise awareness about the importance of accurately diagnosing and managing penicillin allergies. The American Academy of Allergy, Asthma & Immunology (AAAAI) is at the forefront of this effort, providing valuable resources and advocating for the PAVE Act. By working together, healthcare providers, patients, and policymakers can help ensure that patients receive the best possible care and that antibiotic resistance is reduced.